TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.
Address
880 WINTER STREET
WALTHAM, MA 02451
Founded
2018
Number of Employees
154
Website
http://www.tscan.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)